Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P T Taylor

Showing results (21-30 of 57) with videos related to

Pageof 6
Sort By:
International Journal of Radiation Oncology, Biology, Physics|October 1, 1988
Concomitant 5-fluorouracil, mitomycin-C, and radiotherapy for advanced gynecologic malignanciesL S Evans, C R Kersh, W C Constable, et al.
American Journal of Obstetrics and Gynecology|March 1, 1976
Carcinoma in situ of the vagina following treatment for carcinoma of the cervix: a distinctive clinical entityG W Geelhoed, D E Henson, P T Taylor, et al.
Australian Journal of Public Health|December 1, 1994
Diagnostic testing during pregnancy: a descriptive analysis of utilisation dataR L Rushworth, S M Bell, M I Rob, et al.
Cancer Research|November 15, 1994
Inhibition of gamma-glutamyl transpeptidase activity by acivicin in vivo protects the kidney from cisplatin-induced toxicityM H Hanigan, B C Gallagher, P T Taylor, et al.
Obstetrics and Gynecology|November 5, 1999
Late uterine wedge resection of placenta incretaJ A Schnorr, J S Singer, E J Udoff, et al.
The New England Journal of Medicine|February 24, 1972
A method for dinitrochlorobenzene contact sensitization. A clinicopathological studyW J Catalona, P T Taylor, A S Rabson, et al.
The British Journal of Radiology|July 1, 1980
Dose variations in pelvic radiotherapyA L Huddleston, P T Taylor, D Elkon, et al.
British Journal of Cancer|September 16, 1999
Human germ cell tumours: expression of gamma-glutamyl transpeptidase and sensitivity to cisplatinM H Hanigan, H F Frierson, V M Abeler, et al.
American Journal of Obstetrics and Gynecology|August 1, 1991
Vulvar squamous cell carcinoma and papillomaviruses: two separate entities?W A Andersen, D W Franquemont, J Williams, et al.
Gynecologic Oncology|June 1, 1990
Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease?B Patsner, J W Orr, W J Mann, et al.
Pageof 6

Showing results (21-30 of 57) with videos related to

Sort By:
Pageof 6
International Journal of Radiation Oncology, Biology, Physics|October 1, 1988
Concomitant 5-fluorouracil, mitomycin-C, and radiotherapy for advanced gynecologic malignanciesL S Evans, C R Kersh, W C Constable, et al.
American Journal of Obstetrics and Gynecology|March 1, 1976
Carcinoma in situ of the vagina following treatment for carcinoma of the cervix: a distinctive clinical entityG W Geelhoed, D E Henson, P T Taylor, et al.
Australian Journal of Public Health|December 1, 1994
Diagnostic testing during pregnancy: a descriptive analysis of utilisation dataR L Rushworth, S M Bell, M I Rob, et al.
Cancer Research|November 15, 1994
Inhibition of gamma-glutamyl transpeptidase activity by acivicin in vivo protects the kidney from cisplatin-induced toxicityM H Hanigan, B C Gallagher, P T Taylor, et al.
Obstetrics and Gynecology|November 5, 1999
Late uterine wedge resection of placenta incretaJ A Schnorr, J S Singer, E J Udoff, et al.
The New England Journal of Medicine|February 24, 1972
A method for dinitrochlorobenzene contact sensitization. A clinicopathological studyW J Catalona, P T Taylor, A S Rabson, et al.
The British Journal of Radiology|July 1, 1980
Dose variations in pelvic radiotherapyA L Huddleston, P T Taylor, D Elkon, et al.
British Journal of Cancer|September 16, 1999
Human germ cell tumours: expression of gamma-glutamyl transpeptidase and sensitivity to cisplatinM H Hanigan, H F Frierson, V M Abeler, et al.
American Journal of Obstetrics and Gynecology|August 1, 1991
Vulvar squamous cell carcinoma and papillomaviruses: two separate entities?W A Andersen, D W Franquemont, J Williams, et al.
Gynecologic Oncology|June 1, 1990
Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease?B Patsner, J W Orr, W J Mann, et al.
Pageof 6